ELEV's logo.
Ticker Symbol: ELEV

Elevation Oncology Inc

$7.91 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001783032

Company Profile

Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. The company makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Together with its peers Elevation Oncology works towards a future in which each unique test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. Details on CRESTONE are available at www.NRG1fusion.com.

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: N/A
CEO: N/A
Tags: N/A

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.62
Change: -$0.04 ( -7.26%)
Days Range: $0.58 - $0.67
Beta: 0.36
52wk. High: $5.89
52wk. Low: $0.51
Ytd. Change -36.21%
50 Day Moving Average: $0.68
200 Day Moving Average: $1.70
Shares Outstanding: 42381952

Valuation

Market Cap: 2.7B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A